ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Japan's AGC joins project to develop coronavirus DNA vaccine

Collaboration led by biotech venture hopes to have trials out this summer

Seattle-based AGC Biologics will supply a component for the vaccine underdevelopment. (Photo provided by AGC Biologics)

TOKYO -- Japanese chemical and materials maker AGC said Thursday it has teamed up with an Osaka University-affiliated biotechnology company to help produce a coronavirus vaccine that offers a great mass-manufacturing advantage.

The DNA vaccine project is a collaboration between biotech venture AnGes and Takara Bio, which will handle most of the production work.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more